Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

MPT0E028

Known as: HDAC Inhibitor MPT0E028, MPT 0E028, MPT-0E028 
An orally bioavailable N-hydroxyacrylamide-derived inhibitor of both human pan-histone deacetylase (HDAC) enzymes and the serine/threonine protein… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Background Despite the fact that histone deacetylase (HDAC) inhibitors have been tested to treat various cardiovascular diseases… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2019
2019
BackgroundOncogenic K-Ras signaling highly relies on the canonical Ras/MEK/ERK pathway to contribute to pancreatic cancer… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2018
2018
  • Clinical Cancer Research
  • 2018
  • Corpus ID: 49645856
In the original version of this article (1), the authors provided incorrect files for Figs. 1E, 4, 5B, and 6E. In Fig. 1E… Expand
2015
2015
Histone deacetylase (HDAC) inhibitor has been a promising therapeutic option in cancer therapy due to its ability to induce… Expand
2014
2014
Purpose: To investigate the antitumor activities of a histone deacetylase (HDAC) inhibitor, MPT0E028, plus sorafenib in liver… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2014
2014
Purpose: To investigate the antitumor activities of a histone deacetylase (HDAC) inhibitor, MPT0E028, plus sorafenib in liver… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2013
Highly Cited
2013
Epidermal growth factor receptor (EGFR), which promotes cell survival and division, is found at abnormally high levels on the… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
2012
2012
Recently, histone deacetylase (HDAC) inhibitors have emerged as a promising class of drugs for treatment of cancers, especially… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2